Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management
about
sameAs
Antipsychotics in the treatment of autismQuetiapine monotherapy for bipolar depressionReduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialQuantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis.Schizophrenia: overview and treatment options.Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Ziprasidone in the treatment of mania in bipolar disorder.Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studiesExtrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg: an 11-year retrospective analysis.Comparative effects of Rauwolfia vomitoria and chlorpromazine on social behaviour and pain.Antipsychotics dosage and antiparkinsonian prescriptions.Concomitant medication of psychoses in a lifetime perspective.Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)Anticholinergic use in children and adolescents after initiation of antipsychotic therapyEconomic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potTreatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.Antipsychotic drug use and community-acquired pneumoniaOrally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies.Neurologic Complications of Commonly Used Drugs in the Hospital Setting.DBS in Tourette syndrome: where are we standing now?Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009).Severity of illness and extra pyramidal symptoms as predictors for oral diseases among patients with schizophrenia.Hyperkinetic Movement Disorder Emergencies.Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 InteractionIncidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies.Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.Tardive dyskinesia and other movement disorders secondary to aripiprazole.Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009).Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice.A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder.The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).Metoclopramide, an increasingly recognized cause of tardive dyskinesia.
P2860
Q22241891-4A671FE4-5AE4-4B31-A4BD-8E96D1182C8AQ24644541-3CA06605-AF2A-4696-97D8-CBF545CD6AD4Q30524246-D469E46A-5EA5-47B8-91B5-C89313374F4FQ33898356-94666F64-39AA-4B51-AFD5-D64E3EEC087DQ34070862-D9275C48-8B37-4053-AE83-8681F56C6431Q34154951-F8644199-107F-44A2-A74A-DFCDE3DAA4F4Q34574179-D02163DF-D313-4B4C-9566-29DA2DE99E06Q34746791-E16A4F14-6D28-44AD-8720-C587D1383ED5Q34966022-43D870B0-2483-45B0-9B73-7D77DC5060BFQ35062673-92CCDB09-F102-4C34-8D8B-E76FEA94ADAAQ35195377-4583FE4B-1304-45C1-A942-67E6D99F6520Q35913566-AAD814F3-7B11-4DC3-821E-B01EFB52309AQ36054627-90848A94-3377-4047-A33F-62A5D29534A5Q36420453-259BB731-54C9-44E1-B44C-4E0382D49AD0Q36473504-A2FE9C3F-E140-4090-8990-75FB6B9063C2Q37212444-44AE3E78-E4EB-4F94-9321-E40849A0126AQ37492362-F827F6AF-AE4A-4A84-A6FF-D61ECD60F679Q37591807-6C147248-B269-4AD5-ACC7-FE7C48A9B09FQ37722508-70012AA8-AC28-4573-9BEF-DD656CE0EC8FQ37851853-08F10543-3E67-4623-8E6B-C3F05F605599Q37985887-A7F3AF8A-0B56-4066-B8B1-35CDA118EB64Q38056901-881565A1-AAA8-4378-B1BB-67AFACB5A11EQ38504536-63A06A29-CFAF-4636-9A91-1094184FB084Q38746169-978C9565-D8D2-4ADB-95F7-BB63D07F3E4CQ38840810-D3C9C5BB-3284-4CFA-9A4D-025C0AEDA602Q38920515-574C4BF8-A5CA-4F47-9FFB-907BE9BEBFC0Q38950803-37DA70E9-FB94-44EC-98B9-0A5FBF7107B8Q39002654-02896FA8-52A2-46E9-BFAE-D7CEFD03505BQ39123656-9527487D-8A61-47B3-B0A3-21688D5F47D7Q40626667-AA547547-EF60-45CE-A91A-5AD8CFCBE826Q41429342-A7224FF2-49BC-4F4A-8401-8C56FFBC9627Q41862402-CC28FF6C-3012-45DD-83CE-EAD1BACF9D33Q44152748-ECB34DF4-4F9E-40AE-84BD-54FCCF6EA150Q44208517-85B59B8C-B786-4395-899D-FC189F791357Q45282349-C1FF29AB-3298-4929-8C6E-198D58886DF0Q45835487-A3A9FDC2-711F-4D4E-BB61-8DD6D9E1A036Q46297168-C56324C2-128F-4C12-827A-D1916F8E2722Q46305146-E087AFA4-B950-42A3-8446-F3A922510482Q46633043-4C150433-E5D0-4DA3-A606-2BA392A2907DQ46789002-99BEA6E1-071E-482D-BCC6-33244B92A35F
P2860
Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Extrapyramidal symptoms with a ...... nce, prevention and management
@ast
Extrapyramidal symptoms with a ...... nce, prevention and management
@en
Extrapyramidal symptoms with a ...... nce, prevention and management
@nl
type
label
Extrapyramidal symptoms with a ...... nce, prevention and management
@ast
Extrapyramidal symptoms with a ...... nce, prevention and management
@en
Extrapyramidal symptoms with a ...... nce, prevention and management
@nl
altLabel
Extrapyramidal Symptoms with Atypical Antipsychotics
@ast
Extrapyramidal Symptoms with Atypical Antipsychotics
@en
prefLabel
Extrapyramidal symptoms with a ...... nce, prevention and management
@ast
Extrapyramidal symptoms with a ...... nce, prevention and management
@en
Extrapyramidal symptoms with a ...... nce, prevention and management
@nl
P3181
P1433
P1476
Extrapyramidal Symptoms with Atypical Antipsychotics
@en
Extrapyramidal symptoms with a ...... nce, prevention and management
@en
P2093
Joseph M Pierre
P304
P3181
P356
10.2165/00002018-200528030-00002
P407
P577
2005-01-01T00:00:00Z
P6179
1052120625